Giredestrant Outperforms Standard-of-Care Endocrine Therapy in Breast Cancer

Results from the Phase III lidERA clinical trial show that giredestrant, an adjuvant therapy for early-stage hormone receptor-positive (HR+), HER2-negative breast cancer, significantly reduced the risk of recurrence compared to standard endocrine therapies after surgery. Presented today at the San Antonio Breast Cancer Symposium (SABCS), these findings could mark the first major shift in adjuvant therapy for breast cancer in over 25 years.

“This is perhaps one of the most important breast cancer advances in recent years for hormone receptor-positive disease,” said Aditya Bardia, MD, MPH, professor of medicine at the University of California, Los Angeles (UCLA), director of translational research integration at the UCLA Jonsson Comprehensive Cancer Center, and principal investigator of t